Press release
Myopic Macular Degeneration Market to Grow at 8.0% CAGR by 2034
Myopic Macular Degeneration Market
Myopic Macular Degeneration (MMD), also referred to as myopic maculopathy or pathological myopia, is a progressive retinal condition that occurs in individuals with high myopia. Characterized by degeneration of the macula, choroidal neovascularization, and retinal atrophy, MMD is a leading cause of irreversible vision loss in working-age adults, particularly in East Asia.
The rapid rise in global myopia prevalence-driven by urbanization, lifestyle changes, and increased screen time-has dramatically expanded the patient pool for MMD. With myopia projected to affect nearly half of the world's population by 2050, the Myopic Macular Degeneration Market is gaining significant traction. Innovations in anti-VEGF biologics, regenerative therapies, and imaging technologies are improving patient outcomes and fueling market growth.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/72234
Market Overview
• Market Size (2024): Estimated at USD 3.4 billion
• Forecast (2034): Expected to reach USD 7.5 billion
• CAGR (2024-2034): Projected at 8.0%
Key Growth Drivers
• Rising prevalence of high myopia, especially among younger populations.
• Expanding use of anti-VEGF therapies for myopic choroidal neovascularization.
• Growing awareness of early MMD detection and intervention.
• Technological advancements in retinal imaging and diagnostics.
Key Challenges
• High cost of biologic therapies limiting widespread access.
• Recurrence of choroidal neovascularization requiring repeated injections.
• Limited availability of specialized retinal care in rural regions.
• Lack of curative therapies; current options mainly slow disease progression.
Leading Players
Novartis (Lucentis, Beovu), Bayer (Eylea), Regeneron Pharmaceuticals, Roche/Genentech, Samsung Bioepis (biosimilars), Kubota Vision, and ophthalmic device innovators like Topcon and Carl Zeiss Meditec.
Segmentation Analysis
By Therapy Type
• Anti-VEGF Biologics (Ranibizumab, Aflibercept, Bevacizumab, Emerging Biosimilars)
• Laser Photocoagulation & Photodynamic Therapy (PDT)
• Regenerative & Cell Therapies (emerging)
• Supportive Treatments (Vision Aids, Rehabilitation Programs)
By Route of Administration
• Intravitreal Injections
• Systemic Administration (rare)
• Future Sustained-Release Implants
By Disease Stage
• Early MMD
• Moderate MMD
• Advanced MMD with Choroidal Neovascularization
By End User
• Hospitals & Ophthalmology Clinics
• Ambulatory Surgical Centers
• Specialty Retina Centers
• Research & Academic Institutes
Segmentation Summary
Anti-VEGF biologics dominate the market, particularly Ranibizumab (Lucentis) and Aflibercept (Eylea), which are widely used to treat myopic CNV. However, the pipeline of sustained-release implants and regenerative retinal therapies is expected to be the fastest-growing segment, aiming to reduce treatment burden and restore vision.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/72234/myopic-macular-degeneration-mmd-market
Regional Analysis
North America
• 2024 Market Size: USD 1.2 billion
• 2034 Forecast: USD 2.6 billion
• CAGR: 8.1%
The U.S. dominates due to high biologics adoption, strong insurance coverage, and advanced retinal care facilities.
Europe
• 2024 Market Size: USD 0.9 billion
• 2034 Forecast: USD 1.9 billion
• CAGR: 7.9%
Germany, France, and the U.K. lead adoption, supported by structured reimbursement and clinical trial activity.
Asia-Pacific
• 2024 Market Size: USD 1.0 billion
• 2034 Forecast: USD 2.7 billion
• CAGR: 9.2%
China, Japan, and South Korea have the highest prevalence of high myopia and MMD, making Asia-Pacific the fastest-growing region in this market.
Middle East & Africa
• 2024 Market Size: USD 0.15 billion
• 2034 Forecast: USD 0.3 billion
• CAGR: 7.4%
Saudi Arabia and UAE are investing in advanced ophthalmology centers, while Africa faces challenges in access and awareness.
Latin America
• 2024 Market Size: USD 0.15 billion
• 2034 Forecast: USD 0.3 billion
• CAGR: 7.2%
Brazil and Mexico are driving regional adoption, supported by government-backed vision health programs.
Regional Summary
Asia-Pacific dominates the patient pool due to high myopia prevalence, while North America leads in biologics adoption. Europe shows strong structural growth, and Latin America & MEA offer untapped opportunities.
Market Dynamics
Key Growth Drivers
• Global surge in myopia prevalence, especially in children and young adults.
• Strong efficacy of anti-VEGF injections in preserving vision in MMD patients.
• Growth of AI-driven retinal imaging enabling earlier diagnosis and monitoring.
• Rising patient preference for minimally invasive and long-acting treatments.
Key Challenges
• Repeated anti-VEGF injections cause patient burden and adherence issues.
• Limited reimbursement for advanced biologics in emerging economies.
• Lack of therapies addressing underlying myopic degeneration.
• Clinical and genetic complexity of pathological myopia complicates treatment.
Latest Trends
• Launch of biosimilars for anti-VEGF therapies, improving affordability.
• Clinical trials exploring gene and stem cell therapies for retinal regeneration.
• Development of sustained-release anti-VEGF implants to reduce injection frequency.
• Increasing adoption of teleophthalmology and AI diagnostics in early detection.
Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72234
Competitor Analysis
Key Companies
• Novartis - Strong with Lucentis and Beovu in the anti-VEGF space.
• Bayer & Regeneron - Leaders with Aflibercept (Eylea) for CNV treatment.
• Roche/Genentech - Advancing long-acting anti-VEGF therapies.
• Samsung Bioepis & Other Biosimilar Players - Making biologics more affordable.
• Kubota Vision - Developing innovative therapies for progressive myopia.
• Topcon & Carl Zeiss Meditec - Leaders in retinal imaging and diagnostics.
Competitive Dynamics
The MMD market is dominated by anti-VEGF biologics, but competition is intensifying with the entry of biosimilars and long-acting delivery systems. Regenerative medicine and gene therapy innovators are set to redefine the landscape over the next decade. Strategic partnerships between pharma giants and biotech startups will accelerate the transition toward next-generation treatments.
Conclusion
The Myopic Macular Degeneration (MMD) Market is expected to grow from USD 3.4 billion in 2024 to USD 7.5 billion by 2034, at a CAGR of 8.0%.
Opportunities Ahead
• Expansion of biosimilars and cost-effective biologics.
• Growth in regenerative and gene-based therapies.
• Rising investments in Asia-Pacific retinal health infrastructure.
• Integration of AI-driven retinal diagnostics into routine care.
This report is also available in the following languages : Japanese (近視性黄斑変性症(MMD) - 市場), Korean (근시성 황반변성(MMD) - 시장), Chinese (近视黄斑变性(MMD)--市场), French (Dégénérescence maculaire myopique (DMM) - Marché), German (Myopische Makuladegeneration (MMD) - Markt), and Italian (Degenerazione maculare miopica (MMD) - Mercato), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/72234
Our More Reports:
Secondary Hyperparathyroidism Market
https://exactitudeconsultancy.com/reports/72046/secondary-hyperparathyroidism-market
Renal Insufficiency Market
https://exactitudeconsultancy.com/reports/72044/renal-insufficiency-market
Impaired Glucose Tolerance Market
https://exactitudeconsultancy.com/reports/72042/impaired-glucose-tolerance-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Myopic Macular Degeneration Market to Grow at 8.0% CAGR by 2034 here
News-ID: 4192249 • Views: …
More Releases from Exactitude Consultancy
Neurotrophic Keratitis Market Poised for Significant Growth at 8.1% CAGR, Expect …
Introduction
Neurotrophic keratitis (NK) is a rare, degenerative corneal disease caused by impaired corneal innervation, leading to reduced healing capacity, persistent epithelial defects, and potential corneal ulceration or perforation. It is often secondary to conditions such as herpes simplex infection, diabetes, trigeminal nerve injury, or ocular surgeries. Left untreated, NK can result in permanent vision loss.
Historically, management options were limited to supportive care such as lubricants, tarsorrhaphy, or amniotic membrane transplantation.…
Limbal Stem Cell Deficiency Market to Grow at 9.1% CAGR by 2034
Introduction
Limbal Stem Cell Deficiency (LSCD) is a rare but severe ocular surface disorder caused by the loss or dysfunction of limbal stem cells, which are responsible for maintaining and regenerating the corneal epithelium. Patients with LSCD experience chronic pain, recurrent epithelial breakdown, persistent inflammation, and progressive vision loss. Common causes include chemical burns, severe infections, autoimmune diseases, genetic disorders, and iatrogenic damage from multiple ocular surgeries.
Until recently, corneal transplantation was…
Graves' Ophthalmopathy Market to Grow at 8.2% CAGR by 2034
Introduction
Graves' ophthalmopathy, also known as thyroid eye disease (TED), is an autoimmune disorder associated with hyperthyroidism and Graves' disease. It is characterized by inflammation and tissue remodeling around the eyes, leading to symptoms such as bulging eyes (exophthalmos), double vision, pain, and, in severe cases, vision impairment.
The disease has a profound impact on patients' quality of life, requiring both systemic and ophthalmic management.
As the prevalence of thyroid-related autoimmune disorders…
Fuchs' Endothelial Corneal Dystrophy Market to Grow at 7.8% CAGR, Reaching USD 8 …
Introduction
Fuchs' Endothelial Corneal Dystrophy (FECD) is the most common type of corneal endothelial dystrophy, primarily affecting the innermost corneal layer known as the endothelium. Characterized by endothelial cell loss, corneal edema, and vision impairment, FECD often manifests in individuals over the age of 40 and progresses gradually. If left untreated, the condition can cause severe vision loss, requiring corneal transplantation or advanced surgical interventions.
With the global population aging rapidly, FECD…
More Releases for MMD
MMD Services Celebrates 25 Years of Excellence in the DFW Area
Image: https://www.getnews.info/wp-content/uploads/2024/06/1719323671.jpeg
MMD Services announces the completion of 25 years of service in the DFW area.
MMD Services, a woman-owned, family-operated company, has proudly announced the completion of 25 years of dedicated service in the Dallas-Fort Worth (DFW) area. The company offers a comprehensive suite of services, providing in-house design, fabrication, fine art services, interactive technology integration, and lighting design.
"We are delighted to announce that we are celebrating 25 years of excellence…
Visually stunning and feature-rich MMD launches the Philips 346P1CRH monitor
Amsterdam, 10 March 2020 - MMD, the leading display specialist and brand license partner for Philips monitors, announces the launch of the 34" (86.36 cm) Philips 346P1CRH LCD monitor. Featuring a curved UWQHD display with DisplayHDR 400, this monitor delivers an outstanding visual performance in addition to offering a host of convenient connectivity features such as a built-in USB-C docking station and KVM switch, and a wide array of technologies…
Press Invitation to gamescom: AOC and MMD present new gaming monitors at gamesco …
Amsterdam, 31 July 2019 – Display specialists AOC and MMD, brand license partner for Philips monitors, will take this year’s gamescom as an opportunity to present their wide range of gaming monitors.
AOC will underline its leading role in the gaming monitor market with some innovations showcased at the booth and during press meetings. This will include AOC’s brand new mainstream gaming models as well as high-end, premium displays from…
MMD launches the world’s greenest monitor Philips 241B7QGJEB
Amsterdam, 15 January 2019 – MMD, the leading display specialist and brand license partner for Philips monitors, announces the imminent release of the Philips 241B7QGJEB Full HD monitor. This 24" (23.8”) LCD monitor is the new benchmark for green monitors, offering ecologically-minded professionals a powerful tool for boosting performance at work while respecting the environment. In addition to its industry-first energy efficiency, fully recyclable packaging, and compliance with multiple international…
Performance meets design: MMD launches Philips 276E8VJSB monitor
- 4K Ultra HD technology for sharp, clear images
- 10-bit display for bright, beautiful colours
- Slim, contemporary design for easy elegance
Amsterdam, 19 October 2018 – MMD, the leading display specialist and brand license partner for Philips monitors, announces the launch of the very first 4K monitor in their E Line portfolio. The competitively priced Philips 276E8VJSB LCD monitor is a 27" (68.6 cm) Ultra HD monitor equipped with the latest technology for ultra-clear…
AOC and MMD Philips Monitors combine sales activities
• One of the largest sales organisations for monitors in the United Kingdom and Ireland is created - synergy effects and specialised contacts optimise communication for customers: Only one single point of contact with more time for customer-specific requirements.
• Wide product portfolio of the two monitor specialists AOC and Philips offers the perfect solution for every requirement.
• Paul Butler is the Regional Sales Director of the new organisation
Amsterdam, 21 December 2016 – The…
